CG Oncology (NASDAQ:CGON) Stock Price Down 6%

CG Oncology, Inc. (NASDAQ:CGON)’s stock price fell 6% during trading on Monday . The company traded as low as $36.90 and last traded at $37.38. 105,254 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 661,810 shares. The stock had previously closed at $39.75.

Wall Street Analyst Weigh In

A number of research firms have commented on CGON. The Goldman Sachs Group began coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 price target on the stock. Cantor Fitzgerald began coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They issued an “overweight” rating and a $75.00 price target on the stock. Morgan Stanley began coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They issued an “overweight” rating and a $55.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a research report on Thursday, April 4th.

CG Oncology Stock Performance

The firm has a 50-day moving average of $41.33.

Insider Transactions at CG Oncology

In related news, Director Hong Fang Song bought 263,157 shares of CG Oncology stock in a transaction dated Monday, January 29th. The shares were bought at an average cost of $19.00 per share, for a total transaction of $4,999,983.00. Following the completion of the transaction, the director now owns 613,928 shares of the company’s stock, valued at $11,664,632. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Hong Fang Song bought 263,157 shares of CG Oncology stock in a transaction dated Monday, January 29th. The shares were bought at an average cost of $19.00 per share, for a total transaction of $4,999,983.00. Following the completion of the transaction, the director now owns 613,928 shares of the company’s stock, valued at $11,664,632. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Decheng Capital Global Life Sc acquired 400,000 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $7,600,000.00. Following the completion of the acquisition, the insider now directly owns 400,000 shares of the company’s stock, valued at $7,600,000. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 666,472 shares of company stock worth $12,662,968.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.